Sickle cell disease (SCD) is a multisystemic disorder, the pathology being driven by recurrent inflammation particularly during a vaso-occlusive crisis.
| INTRODUC TI ON
Sickle cell disease (SCD) is caused by the presence of an abnormal hemoglobin S (HbS) which results from a single base substitution in the beta-globin gene of hemoglobin. Polymerization of deoxygenated-HbS leads to "sickling" of red blood cells, resulting in chronic hemolytic anemia and recurrent episodes of acute vaso-occlusive pain. All patients have progressive end-organ damage and a reduced life expectancy. SCD is a multisystem disorder with multiple organ damage associated with recurring inflammation caused by tissue ischemia, reperfusion injury, and vascular damage. [1] [2] [3] [4] [5] Several markers of inflammation are elevated in SCD, including total white cell count, secretory phospholipase A2, interleukins, prostaglandin-E2, and Tumor Necrosis Factorα. [6] [7] [8] [9] [10] Acute phase reactants, proteins which rise or fall as a reaction to proinflammatory cytokines, include C-reactive protein (CRP) and ferritin. Platelets and haptoglobin are also elevated during inflammation. 11 However, the inherent variability of the plasma levels of these proteins challenges the ability to identify a biomarker with sufficient sensitivity and specificity for detecting acute crises.
For instance, raised CRP levels in steady state are correlated with increased frequency of pain crisis and elevated levels are found during acute pain crises and acute chest syndrome. 8, 9, 12 However, studies have found significant interindividual variability, a short half-life and a wide reference range for this marker. 13 As inflammation is a key biological event accompanying acute vaso-occlusive crisis, a specific biomarker of inflammation would potentially be useful to determine disease activity in SCD.
GlycA shows promise as a biomarker of inflammation and disease severity in chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, and systemic lupus erythematosus (SLE). [14] [15] [16] [17] GlycA is a composite signal derived from ( 1 H) nuclear magnetic resonance (NMR) spectra of the N-acetyl methyl group protons of the carbohydrate side chains of mainly four positive acute phase proteins: α1-acid glycoprotein, haptoglobin, α1-antitrypsin, and α1-antichymotrypsin, and one negative acute phase protein, transferrin. 13, [18] [19] [20] [21] Positive acute phase proteins increase, while negative acute phase proteins decrease, in response to inflammation. GlycA has relatively low interindividual variability compared with CRP and appears to have prognostic value as an indicator of treatment response and disease activity. 19 We evaluated the plasma GlycA levels in a cross-sectional sample of patients with SCD and specifically tested its levels in patients experiencing an acute painful vaso-occlusive crisis (VOC).
| MATERIAL S AND ME THODS

| Study definitions
An "acute pain vaso-occlusive crisis" was defined as a visit to the NIH Clinical Center for acute pain without evidence of an 
| Study participants
| Sample processing
Ethylenediaminetetraacetic acid (EDTA) anticoagulated blood samples were collected and centrifuged for 10 minutes at 1200 g. The resulting supernatant plasma was removed by pipetting, transferred to Sarstedt Micro tubes, snap-frozen in liquid nitrogen, and stored at −80°C until use.
Hematological and biochemical parameters were obtained from routine hospital laboratory measurements at steady state and during acute pain crisis.
| GlycA measurements
Aliquots of frozen plasma (500 μL) were thawed at 4°C for 24 hours.
Subsequently, 450 μL was transferred to a cell-strainer capped Falcon™ Round-Bottom Polypropylene (Thermo Fisher Scientific, Hampton, NH, USA) test tubes on the day of analysis. Using previously described methodology, plasma GlycA was quantified in these samples with a 400 MHz proton ( 1 H) NMR spectrometer (Vantera ® Clinical Analyzer, LipoScience Inc., NC, USA). [22] [23] [24] 
| Statistical analysis
| RE SULTS
| Baseline characteristics
Five hundred patients with SCD from Group 1 and Group 2 were included in our study as detailed in Figure 1 . 
| Plasma GlycA levels in SCD
The mean plasma GlycA level was lower in SCD steady state pa- 
| Correlation of plasma GlycA levels with hemolysis markers
There was a negative correlation between plasma GlycA in SCD steady state and LDH (P = 0.0089). Correlations with other hemolysis markers did not reveal significant findings.
| D ISCUSS I ON
Several recent studies of diseases involving chronic vascular inflammation, namely psoriasis 14 and SLE, 17 have found that plasma GlycA levels are higher compared with healthy controls. As SCD is a known proinflammatory condition, we hypothesized that the plasma GlycA levels would also be similarly be elevated among SCD patients compared with healthy controls. 1, 11, 13, 15, 25 We also hypothesized that the plasma GlycA level would be further elevated during VOCs when compared with its level during the steady state, reflecting the increased inflammation accompanying acute pain in SCD. On the con- Ongoing inflammation as a result of recurrent painful vasoocclusive crisis with reperfusion injury is thought to mediate in part the vascular pathobiology of SCD. 1, [26] [27] [28] While elevated CRP levels provided biochemical evidence for inflammation in our patients with SCD, the GlycA values obtained were paradoxically lower than healthy controls and also lower than reported in other inflammatory diseases. 8, 9, 11, 13 For example, studies have shown the plasma GlycA level in rheumatoid arthritis and SLE was 353.8 ± 65.2 μmol/L and 408.0 ± 75.4 μmol/L, respectively, compared with 324.6 ± 70.4 μmol/L in our patients with SCD. 14, 16 We attributed these seemingly contradictory results to hemolysis observed in the patients with SCD, which is not observed in the other two diseases. 29 It would be interesting to compare the GlycA levels in other diseases involving hemolytic anemia where haptoglobin is depleted and there is a less pronounced inflammatory response, such as pyruvate kinase deficiency or hereditary spherocytosis.
The GlycA signal is a compilation of five acute phase proteins, four of which are elevated during inflammation, one of which is haptoglobin. 13, 18 However, haptoglobin is a scavenger of free hemoglobin and becomes rapidly depleted during intravascular hemolysis.
The negative correlation between the plasma GlycA level and LDH, an indirect marker of hemolysis, supports this hypothesis. 12, [30] [31] [32] [33] Our data, therefore, suggest that hemolysis in SCD nullifies GlycA as a valid biomarker of inflammation in SCD. Measuring GlycA in patients with SCD in their steady state also appears to be futile as ongoing chronic hemolysis renders haptoglobin immeasurable. The strengths of this study are the quantification of a novel plasma biomarker of inflammation in a large cohort of patients with SCD and the inclusion of paired samples obtained during steady state and an acute painful crisis. The Vantera ® Clinical Analyzer is an automated NMR spectrometer with an inbuilt deconvolution algorithm designed to ease clinical utility. This design unfortunately limited our ability to interrogate the individual components of the GlycA signal to further investigate the effect of hemolysis on the GlycA measurement. 22 
| CON CLUS ION
GlycA a composite signal derived from five acute phase reactants is not a useful biomarker of inflammation in SCD. Plasma GlycA measurements in patients with SCD appear to be confounded by hemolysis. Further studies are warranted to identify a more specific biomarker of inflammation for this complex disorder.
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